AstraZeneca’s reiteration of its previously announced freeze on investments in U.K. manufacturing has caused alarm among politicians. In the fevered pre-Brexit environment, pro-Remain politicians saw the reiteration of an old position as evidence the split from the U.K. will decimate life science research.
The excitement stems from a comment AstraZeneca chairman Leif Johansson made to French newspaper Le Monde. Johansson said AstraZeneca would maintain its decision not to invest in the U.K. if there is no transition deal that clarifies the terms of the post-Brexit relationship with the European Union. The comment was seized upon by politicians opposed to Brexit.
“More grim #BrexitReality as AstraZeneca halts investment in U.K. No one voted to decimate medical research,” Sarah Wollaston, a pro-Remain MP, doctor and chair of the Health and Social Care Select Committee, wrote on Twitter.
Wollaston was not the only public figure to see implications for U.K. life science research in Johansson’s comments. Phillip Lee, a politician who resigned over the government’s approach to Brexit, made a similar link to Wollaston, stating “we need to keep our world-class research base if we want our pharmaceutical industry to survive and thrive.”
The fears are somewhat divorced from the current reality, though. While certain outcomes to Brexit could feasibly affect AstraZeneca’s investment in R&D in the U.K., as it stands the company is pushing ahead with its projects.
“Things are as they were nearly 18 months ago,” a spokesperson for AstraZeneca said. “The freeze is on the manufacturing side. The Cambridge stuff, the R&D, that’s unchanged.”
While Johansson’s comments were seen as a bombshell in some quarters, they are a continuation of a position AstraZeneca adopted last year. Back then, CEO Pascal Soriot told the Financial Times AstraZeneca was holding off on new investments in U.K. manufacturing until there was clarity over the future regulatory regime and relationship to the EU.
By Nick Paul Taylor
Source: Fierce Biotech
Hybrid closed-loop systems rely on an algorithm to first analyze real-time blood sugar readings from a continuous glucose monitor, then use the results to adjust an insulin pump’s output as needed throughout the day. In this case, the algorithm was developed by Diabeloop, the CGM is a Dexcom G6 sensor, and the insulin pump comes from ViCentra.
Boehringer Ingelheim has acquired bacterial cancer therapy company T3 Pharmaceuticals in a deal that could be worth up to 450 million Swiss francs ($508 million). The addition of Allschwil, Switzerland-based T3 will “significantly expand” the German drugmaker’s immuno-oncology pipeline and aligns with some of the company’s existing R&D programs.
EuroAPI has completed the acquisition of BianoGMP, a contract development and manufacturing organization (CDMO) specializing in oligonucleotides. The acquisition, announced in August, further differentiates its value proposition to support a broader client base across the whole oligonucleotide development continuum, from research to commercialization, EuroAPI said.
